DEPOCYT Side Effects

6127524-3 | Demyelination, Diplegia, Faecal Incontinence, Guillain-barre Syndrome, Meningitis Viral, Nervous System Disorder, Pain In Extremity, Peripheral Sensory Neuropathy
on Mar 04, 2009 Female patient from GERMANY , 68 years of age, was diagnosed with prophylaxis and was treated with Depocyt (View Usage). Patient experienced the following unwanted or unexpected effects: demyelination, diplegia, faecal incontinence, guillain-barre syndrome (What is guillain-barre syndrome?), meningitis viral, nervous system disorder, pain in extremity, peripheral sensory neuropathy. Depocyt dosage: 50 Mg; 3x; Inth. During the same period patient was treated with DEXAMETHASONE (CON.) (View Dexamethasone (con.) Review and Dexamethasone (con.) Label ), VINCRISTINE (CON.) (View Vincristine (con.) Review and Vincristine (con.) Label ), IDARUBICIN (CON.) (View Idarubicin (con.) Review and Idarubicin (con.) Label ), CYCLOPHOSPHAMIDE (CON.) (View Cyclophosphamide (con.) Review and Cyclophosphamide (con.) Label ), ARA C (CON.) (View Ara-c (con.) Review and Ara-c (con.) Label ), MIRTAZAPINE (CON.) (View Mirtazapine (con.) Review and Mirtazapine (con.) Label ), LEVOFLOXACIN (CON.) (View Levofloxacin (con.) Review and Levofloxacin (con.) Label ), ACETAMINOPHEN (CON.) (View Acetaminophen (con.) Review and Acetaminophen (con.) Label ). Patient was hospitalized.

6111627-3 | Epistaxis, Pneumonia Escherichia, Pneumonia Klebsiella, Thrombocytopenia, Unevaluable Event
Patient was taking Depocyt (View Usage). Patient had the following side effects: epistaxis, pneumonia escherichia, pneumonia klebsiella, thrombocytopenia, unevaluable event on Feb 19, 2009 from FRANCE Additional patient health information: Male patient , 58 years of age, weighting 136.7 lb, was diagnosed with central nervous system lymphoma and. Depocyt dosage: 50 Mg; X3; Inth. During the same period patient was treated with METHOTREXATE (5300 Mg; Qd; Iv) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (2 Mg; Qd; Iv) (View Vincristine Review and Vincristine Label ), METHYLPREDNISOLONE (80 Mg; Qd; Iv) (View Methylprednisolone Review and Methylprednisolone Label ), RITUXIMAB (RITUXIMAB) (650 Mg; Qd; Iv) (View Rituximab (rituximab) Review and Rituximab (rituximab) Label ), DOXORUBICIN HCL (106 Mg; Qd; Iv) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYCLOPHOSPHAMIDE (2640 Mg; Qd; Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ), ARACYTINE (ARACYTINE) (170 Mg; Qd; Iv) (View Aracytine (aracytine) Review and Aracytine (aracytine) Label ), METHYLPREDNISOLONE 16MG TAB (80 Mg; Qd; Iv) (View Methylprednisolone 16mg Tab Review and Methylprednisolone 16mg Tab Label ). Patient was hospitalized.

6107482-8 | Neurotoxicity, Paraesthesia, Peroneal Nerve Palsy, Polyneuropathy
Adverse event was reported on Feb 20, 2009 by a Female patient taking Depocyt (View Usage) (Dosage: 40 Mg; X2; Inth) was diagnosed with central nervous system leukaemia and. Location: GERMANY , 50 years of age, After Depocyt was administered, patient had the following side effects: neurotoxicity, paraesthesia, peroneal nerve palsy, polyneuropathy.

6107477-4 | Disease Progression, Headache, Intracranial Pressure Increased, Papilloedema, Vision Blurred
on Jan 05, 2009 Female patient from DENMARK , 20 years of age, was diagnosed with leukaemia and was treated with Depocyt (View Usage). Patient experienced the following unwanted or unexpected effects: disease progression, headache (What is headache?), intracranial pressure increased, papilloedema, vision blurred. Depocyt dosage: 50 Mg; 1x;inth. Patient was hospitalized.


6088057-6 | Catheter Sepsis
on Feb 05, 2009 Male patient from FRANCE , 56 years of age, weighting 178.6 lb, was diagnosed with metastases to meninges, non-hodgkin's lymphoma and was treated with Depocyt (View Usage). Patient had the following side effects: catheter sepsis. Depocyt dosage: 50 Mg; Qd; Inth. During the same period patient was treated with RITUXIMAB (RITUXIMAB) (740 Mg; Qd; Iv) (View Rituximab (rituximab) Review and Rituximab (rituximab) Label ), METHOTREXATE (5900 Mg; Qd; Iv) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (2 Mg; Qd; Iv) (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (118 Mg; Qd; Iv) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYCLOPHOSPHAMIDE (2940 Mg; Qd; Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ), METHYLPREDNISOLONE (400 Mg; Qd; Iv) (View Methylprednisolone Review and Methylprednisolone Label ), METHYLPREDNISOLONE 16MG TAB (192 Mg; Qd; Iv) (View Methylprednisolone 16mg Tab Review and Methylprednisolone 16mg Tab Label ). Patient was hospitalized.

6085318-1 | Dysarthria, Fall, Foot Fracture, Gait Disturbance, Leukoencephalopathy, Malignant Neoplasm Progression, Mental Impairment, Neuralgia
Patient was taking Depocyt (View Usage). After Depocyt was administered, patient had the following side effects: dysarthria, fall (What is fall?), foot fracture, gait disturbance, leukoencephalopathy, malignant neoplasm progression, mental impairment, neuralgia on Jan 26, 2009 from GERMANY Additional patient health information: Male patient , 42 years of age, was diagnosed with metastases to meninges and. Depocyt dosage: 50 Mg;qm;inth. During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ). Patient was hospitalized.

6085302-8 | Dysstasia, Fall, Hypoaesthesia, Leukaemia Recurrent, Muscular Weakness, Pain
Adverse event was reported on Feb 04, 2009 by a Female patient taking Depocyt (View Usage) (Dosage: 50 Mg;qow;inth) was diagnosed with central nervous system leukaemia and. Location: SWEDEN , 50 years of age, Patient experienced the following unwanted or unexpected effects: dysstasia, fall (What is fall?), hypoaesthesia, leukaemia recurrent, muscular weakness, pain (What is pain?). During the same period patient was treated with DASATINIB (View Dasatinib Review and Dasatinib Label ), BETAMETHASONE (View Betamethasone Review and Betamethasone Label ), TRAMADOL HCL (View Tramadol Hcl Review and Tramadol Hcl Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), PARACETAMOL (View Paracetamol Review and Paracetamol Label ), ESTRADIOL W/MEDROXYPROGESTERONE (View Estradiol W/medroxyprogesterone Review and Estradiol W/medroxyprogesterone Label ).

6085295-3 | Febrile Bone Marrow Aplasia, Headache, Meningitis, Purulence
on Nov 14, 2008 Male patient from FRANCE , 39 years of age, weighting 178.6 lb, was diagnosed with metastases to meninges, meningitis bacterial and was treated with Depocyt (View Usage). Patient had the following side effects: febrile bone marrow aplasia, headache (What is headache?), meningitis (What is meningitis?), purulence. Depocyt dosage: 50 Mg; Qd; Inth. During the same period patient was treated with SOLU MEDROL (50 Mg; Qd; Iv) (View Solu-medrol Review and Solu-medrol Label ), VINCRISTINE SULFATE (2 Mg, Qd; Iv) (View Vincristine Sulfate Review and Vincristine Sulfate Label ), METHOTREXATE (3000 Mg; Qd; Iv) (View Methotrexate Review and Methotrexate Label ), ADRIBLASTINE (DOXORUBICIN HYDROCHLORIDE) (60 Mg; Qd; Iv) (View Adriblastine (doxorubicin Hydrochloride) Review and Adriblastine (doxorubicin Hydrochloride) Label ), ENDOXAN /00021101/ (CYCLOPHOSPHAMIDE) (1000 Mg; Qd; Iv) (View Endoxan /00021101/ (cyclophosphamide) Review and Endoxan /00021101/ (cyclophosphamide) Label ), DEPO MEDROL (80 Mg; Qd;po) (View Depo-medrol Review and Depo-medrol Label ), RITUXIMAB (RITUXIMAB) (750 Mg;qd;iv) (View Rituximab (rituximab) Review and Rituximab (rituximab) Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ). Patient was hospitalized.

6009091-8 | Demyelination, Guillain-barre Syndrome
on Dec 02, 2008 Female patient from GERMANY , 68 years of age, was diagnosed with prophylaxis and was treated with Depocyt (View Usage). After Depocyt was administered, patient had the following side effects: demyelination, guillain-barre syndrome (What is guillain-barre syndrome?). Depocyt dosage: 50 Mg; 3x; Inth. Patient was hospitalized.

5979410-7 | Cauda Equina Syndrome, Disease Progression
Patient was taking Depocyt (View Usage). Patient experienced the following unwanted or unexpected effects: cauda equina syndrome, disease progression on Nov 12, 2008 from UNITED KINGDOM Additional patient health information: Female patient , 53 years of age, was diagnosed with lymphoma (What is lymphoma?) and. Depocyt dosage: 50 Mg; Qm; Inth. Patient was hospitalized and became disabled.

5958179-6 | Eye Movement Disorder, Hypoglossal Nerve Paresis, Leukoencephalopathy, Nausea, Nervous System Disorder, Paraneoplastic Syndrome
Adverse event was reported on Jul 17, 2008 by a Female patient taking Depocyt (View Usage) (Dosage: 50 Mg) was diagnosed with mantle cell lymphoma and. Location: GERMANY , 71 years of age, weighting 165.0 lb, Patient had the following side effects: eye movement disorder, hypoglossal nerve paresis, leukoencephalopathy, nausea (What is nausea?), nervous system disorder, paraneoplastic syndrome. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), DEXAMETHASONE 0.5MG TAB (View Dexamethasone 0.5mg Tab Review and Dexamethasone 0.5mg Tab Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), ENALAPRIL MALEATE (View Enalapril Maleate Review and Enalapril Maleate Label ), ASPIRIN (View Aspirin Review and Aspirin Label ). Patient was hospitalized.

5920193-4 | Asthenia, Blood Pressure Decreased, Cardiomyopathy, Dyspepsia, Escherichia Sepsis, Pyrexia
on Sep 24, 2008 Female patient from FRANCE , 54 years of age, was diagnosed with metastases to meninges, non-hodgkin's lymphoma and was treated with Depocyt (View Usage). After Depocyt was administered, patient had the following side effects: asthenia, blood pressure decreased, cardiomyopathy (What is cardiomyopathy?), dyspepsia, escherichia sepsis, pyrexia. Depocyt dosage: 50 Mg; Ic. During the same period patient was treated with RITUXIMAB (RITUXIMAB) (685 Mg; Iv) (View Rituximab (rituximab) Review and Rituximab (rituximab) Label ), METHYLPREDNISOLONE 16MG TAB (110 Mg; Qd; Iv) (View Methylprednisolone 16mg Tab Review and Methylprednisolone 16mg Tab Label ), VINCRISTINE (2 Mg; Qd; Iv) (View Vincristine Review and Vincristine Label ), METHOTREXATE (5450 Mg;qd;iv) (View Methotrexate Review and Methotrexate Label ), DOXORUBICIN HCL (109 Mg;qd; Iv) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYCLOPHOSPHAMIDE (450 Mg;bid; Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ), CYTARABINE (180 Mg;qd; Iv) (View Cytarabine Review and Cytarabine Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ). Patient was hospitalized.

5913249-3 | Arachnoiditis, Back Pain, Bone Pain, Dizziness, Headache, Nausea, Paraesthesia
on Sep 24, 2008 Female patient from POLAND , 17 years of age, was diagnosed with metastases to meninges and was treated with Depocyt (View Usage). Patient experienced the following unwanted or unexpected effects: arachnoiditis, back pain (What is back pain?), bone pain, dizziness (What is dizziness?), headache (What is headache?), nausea (What is nausea?), paraesthesia. Depocyt dosage: 50 Mg; 1x; Inth. During the same period patient was treated with GANCICLOVIR (View Ganciclovir Review and Ganciclovir Label ), VINBLASTINE SULFATE (View Vinblastine Sulfate Review and Vinblastine Sulfate Label ), PREDNISONE ACETATE (View Prednisone Acetate Review and Prednisone Acetate Label ). Patient was hospitalized.

5883350-1 | Cauda Equina Syndrome
Patient was taking Depocyt (View Usage). Patient had the following side effects: cauda equina syndrome on Aug 21, 2008 from UNITED KINGDOM Additional patient health information: Male patient , 65 years of age, was diagnosed with metastases to meninges and. Depocyt dosage: 50 Mg; Inth.

5857833-4 | Dysphagia, Mucosal Inflammation, Neutropenia
Adverse event was reported on Aug 08, 2008 by a Male patient taking Depocyt (View Usage) (Dosage: 50 Mg;inth) was diagnosed with metastases to meninges and. Location: BELGIUM , 44 years of age, weighting 147.7 lb, After Depocyt was administered, patient had the following side effects: dysphagia, mucosal inflammation, neutropenia. During the same period patient was treated with DOXORUBICIN HCL (108 Mg; Qd; Iv) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYCLOPHOSPHAMIDE (500 Mg; Qd; Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ), METHOTREXATE (5400 Mg; Qd; Iv) (View Methotrexate Review and Methotrexate Label ), ONCOVIN (2 Mg; Qd) (View Oncovin Review and Oncovin Label ), RITUXIMAB (RITUXIMAB) (675 Mg; Qd; Iv) (View Rituximab (rituximab) Review and Rituximab (rituximab) Label ), SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), LEUCOVORIN CALCIUM (View Leucovorin Calcium Review and Leucovorin Calcium Label ). Patient was hospitalized.

5849013-3 | Central Nervous System Lymphoma, Malignant Neoplasm Progression, Neuralgia, Sensory Disturbance, T-cell Lymphoma Recurrent
on Aug 01, 2008 Male patient from GERMANY , 42 years of age, was diagnosed with metastases to meninges and was treated with Depocyt (View Usage). Patient experienced the following unwanted or unexpected effects: central nervous system lymphoma, malignant neoplasm progression, neuralgia, sensory disturbance, t-cell lymphoma recurrent. Depocyt dosage: 50 Mg;qm;inth. During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ).

5847720-X | Cauda Equina Syndrome, Paresis, Urinary Retention
on Jul 29, 2008 Female patient from GERMANY , 47 years of age, was diagnosed with metastases to meninges and was treated with Depocyt (View Usage). Patient had the following side effects: cauda equina syndrome, paresis, urinary retention. Depocyt dosage: 50 Mg;biw;inth. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), GEMCITABINE HCL (View Gemcitabine Hcl Review and Gemcitabine Hcl Label ), LEVETIRACETAM (View Levetiracetam Review and Levetiracetam Label ), VALPROATE SODIUM (View Valproate Sodium Review and Valproate Sodium Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ).

5844616-4 | Coma, Depressed Level Of Consciousness, Disease Progression, Dyspnoea, Neurotoxicity, Pyrexia
Patient was taking Depocyt (View Usage). After Depocyt was administered, patient had the following side effects: coma, depressed level of consciousness, disease progression, dyspnoea, neurotoxicity, pyrexia on Jul 28, 2008 from FINLAND Additional patient health information: Female patient , 64 years of age, was diagnosed with central nervous system lymphoma and. Depocyt dosage: 50 Mg; 1x; Inth. During the same period patient was treated with IFOSFAMIDE (800 Mg/m**2; ; Iv) (View Ifosfamide Review and Ifosfamide Label ), HOLOXAN (View Holoxan Review and Holoxan Label ), DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

5826205-0 | Acute Lymphocytic Leukaemia, Cauda Equina Syndrome, Clostridium Difficile Toxin Test Positive, Encopresis, Gait Disturbance, Hypoaesthesia, Leukaemia Recurrent, Nervous System Disorder, Neurotoxicity
Adverse event was reported on Jul 04, 2008 by a Male patient taking Depocyt (View Usage) (Dosage: 50 Mg; Q6w; Inth) was diagnosed with leukaemia, nervous system disorder and. Location: SWEDEN , 15 years of age, Patient experienced the following unwanted or unexpected effects: acute lymphocytic leukaemia, cauda equina syndrome, clostridium difficile toxin test positive, encopresis, gait disturbance, hypoaesthesia, leukaemia recurrent, nervous system disorder, neurotoxicity. During the same period patient was treated with SULFAMETHOXAZOLE AND TRIMETHOPRIM (View Sulfamethoxazole And Trimethoprim Review and Sulfamethoxazole And Trimethoprim Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

5824610-X | Facial Palsy, Neurotoxicity, Puncture Site Haemorrhage
on Jul 07, 2008 Male patient from FRANCE , 21 years of age, was diagnosed with leukaemia and was treated with Depocyt (View Usage). Patient had the following side effects: facial palsy, neurotoxicity, puncture site haemorrhage. Depocyt dosage: 50 Mg/qow;inth. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

5804290-X | Ataxia, Balance Disorder, Central Nervous System Inflammation, Disease Progression, Headache, Intracranial Pressure Increased, Neurotoxicity, Papilloedema, Visual Impairment
on Jun 26, 2008 Female patient from UNITED KINGDOM , 33 years of age, was diagnosed with lymphoma (What is lymphoma?) and was treated with Depocyt (View Usage). After Depocyt was administered, patient had the following side effects: ataxia (What is ataxia?), balance disorder, central nervous system inflammation, disease progression, headache (What is headache?), intracranial pressure increased, neurotoxicity, papilloedema, visual impairment. Depocyt dosage: 50 Mg; Inth. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

5804289-3 | Arachnoiditis, Central Nervous System Leukaemia, Colitis, Disease Progression, Encephalopathy, Neurotoxicity, Overdose, Pain
Patient was taking Depocyt (View Usage). Patient experienced the following unwanted or unexpected effects: arachnoiditis, central nervous system leukaemia, colitis, disease progression, encephalopathy, neurotoxicity, overdose, pain (What is pain?) on Jun 27, 2008 from BELGIUM Additional patient health information: Female patient , 77 years of age, was diagnosed with acute lymphocytic leukaemia and. Depocyt dosage: 50 Mg, Qow; Inth. During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), GLAZIDIM (View Glazidim Review and Glazidim Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), CITALOPRAM HYDROBROMIDE (View Citalopram Hydrobromide Review and Citalopram Hydrobromide Label ), ZANTAC (View Zantac Review and Zantac Label ), METFORMIN (View Metformin Review and Metformin Label ), CETIRIZINE HYDROCHLORIDE (View Cetirizine Hydrochloride Review and Cetirizine Hydrochloride Label ). Patient was hospitalized.

5798678-3 | Depressed Level Of Consciousness, Dyspnoea, Neurotoxicity, Pyrexia
Adverse event was reported on Jun 11, 2008 by a Female patient taking Depocyt (View Usage) (Dosage: 50 Mg;1x;inh) was diagnosed with central nervous system lymphoma and. Location: FINLAND , 64 years of age, Patient had the following side effects: depressed level of consciousness, dyspnoea, neurotoxicity, pyrexia. During the same period patient was treated with IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

5794858-1 | Demyelination, Dysarthria, Fall, Foot Fracture, Gait Disturbance, Mental Impairment, Premature Ageing
on Jun 16, 2008 Male patient from GERMANY , 42 years of age, was diagnosed with metastases to meninges and was treated with Depocyt (View Usage). After Depocyt was administered, patient had the following side effects: demyelination, dysarthria, fall (What is fall?), foot fracture, gait disturbance, mental impairment, premature ageing. Depocyt dosage: 50 Mg;qw;inth. During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ).

5794856-8 | Demyelination, Dysarthria, Fall, Foot Fracture, Gait Disturbance, Mental Impairment, Neurotoxicity, Premature Ageing
on Jun 16, 2008 Male patient from GERMANY , 42 years of age, was diagnosed with metastases to meninges and was treated with Depocyt (View Usage). Patient experienced the following unwanted or unexpected effects: demyelination, dysarthria, fall (What is fall?), foot fracture, gait disturbance, mental impairment, neurotoxicity, premature ageing. Depocyt dosage: 50 Mg;qw;inth. During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ).

5779559-8 | Intracranial Pressure Increased, Papilloedema
Patient was taking Depocyt (View Usage). Patient had the following side effects: intracranial pressure increased, papilloedema on May 29, 2008 from UNITED KINGDOM Additional patient health information: Female patient , 33 years of age, was diagnosed with lymphoma (What is lymphoma?) and. Depocyt dosage: 50 Mg; Inth. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ).

5776160-7 | Acute Leukaemia, Disease Progression, Encephalopathy, Pain, Pyrexia
Adverse event was reported on May 30, 2008 by a Female patient taking Depocyt (View Usage) (Dosage: Inth) was diagnosed with acute lymphocytic leukaemia and. Location: BELGIUM , 77 years of age, After Depocyt was administered, patient had the following side effects: acute leukaemia, disease progression, encephalopathy, pain (What is pain?), pyrexia. During the same period patient was treated with METHOTREXATE (CON.) (View Methotrexate (con.) Review and Methotrexate (con.) Label ), CYTARABINE (CON.) (View Cytarabine (con.) Review and Cytarabine (con.) Label ), DEXAMETHASONE (CON.) (View Dexamethasone (con.) Review and Dexamethasone (con.) Label ), GLAZIDIM (CON.) (View Glazidim (con.) Review and Glazidim (con.) Label ). Patient was hospitalized.

5776159-0 | Leukoencephalopathy
on May 28, 2008 Male patient from SPAIN , 42 years of age, was diagnosed with leukaemia and was treated with Depocyt (View Usage). Patient experienced the following unwanted or unexpected effects: leukoencephalopathy. Depocyt dosage: 50 Mg; 1x; Inth. During the same period patient was treated with DASATINIB (DASATINIB) (50 Mg; Tid; Po) (View Dasatinib (dasatinib) Review and Dasatinib (dasatinib) Label ). Patient was hospitalized.

5765026-4 | Convulsion
on Jul 03, 2007 Male patient from UNITED STATES , 48 years of age, weighting 183.9 lb, was diagnosed with metastatic neoplasm and was treated with Depocyt (View Usage). Patient had the following side effects: convulsion. Depocyt dosage: 50 Mg; 1x; Ed. During the same period patient was treated with ATENOLOL (View Atenolol Review and Atenolol Label ), DECADRON (View Decadron Review and Decadron Label ), LOTREL (View Lotrel Review and Lotrel Label ), CALCIUM CARBONATE (View Calcium Carbonate Review and Calcium Carbonate Label ), SENOKOT (View Senokot Review and Senokot Label ), MORPHINE (View Morphine Review and Morphine Label ), PERCOCET (View Percocet Review and Percocet Label ).

5762377-4 | Balance Disorder, Headache, Loss Of Consciousness, Nervous System Disorder, Nuclear Magnetic Resonance Imaging Brain Abnormal, Vertigo
Patient was taking Depocyt (View Usage). After Depocyt was administered, patient had the following side effects: balance disorder, headache (What is headache?), loss of consciousness, nervous system disorder, nuclear magnetic resonance imaging brain abnormal, vertigo on May 16, 2008 from POLAND Additional patient health information: Female patient , 22 years of age, weighting 99.21 lb, was diagnosed with acute lymphocytic leukaemia and. Depocyt dosage: 50 Mg; ; Inth.

5758407-6 | Cardio-respiratory Arrest, Confusional State, Disorientation, Labile Hypertension, Mental Status Changes, Pupillary Reflex Impaired, Unresponsive To Stimuli
Adverse event was reported on Jun 03, 2008 by a Female patient taking Depocyt (View Usage) (Dosage: 50mg X1 Intratrache) was diagnosed with metastases to meninges and. Location: UNITED STATES , 53 years of age, Patient experienced the following unwanted or unexpected effects: cardio-respiratory arrest, confusional state, disorientation, labile hypertension, mental status changes, pupillary reflex impaired, unresponsive to stimuli.

5743625-3 | Radiculitis Lumbosacral
on Apr 22, 2008 Female patient from GERMANY , 64 years of age, weighting 122.1 lb, was treated with Depocyt (View Usage). Patient had the following side effects: radiculitis lumbosacral. Depocyt dosage: 50 Mg;inth. During the same period patient was treated with DEXAMETASON (View Dexametason Review and Dexametason Label ), ESCITALOPRAM (View Escitalopram Review and Escitalopram Label ), ENOXAPARIN SODIUM (View Enoxaparin Sodium Review and Enoxaparin Sodium Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ). Patient was hospitalized.

5742443-X | Neurogenic Bladder, Paresis Anal Sphincter
on Apr 25, 2008 Female patient from GERMANY , 72 years of age, weighting 149.9 lb, was treated with Depocyt (View Usage). After Depocyt was administered, patient had the following side effects: neurogenic bladder, paresis anal sphincter. Depocyt dosage: 50 Mg; X4; Inth. During the same period patient was treated with DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), METHOTREXATE SODIUM (View Methotrexate Sodium Review and Methotrexate Sodium Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), PANTOPRAZOLE (View Pantoprazole Review and Pantoprazole Label ), SODIUM CHLORIDE (View Sodium Chloride Review and Sodium Chloride Label ), ZOPICLONE (View Zopiclone Review and Zopiclone Label ). Patient was hospitalized.

5715817-0 | Inappropriate Antidiuretic Hormone Secretion, Septic Shock
Patient was taking Depocyt (View Usage). Patient experienced the following unwanted or unexpected effects: inappropriate antidiuretic hormone secretion, septic shock on Apr 11, 2008 from SPAIN Additional patient health information: Female patient , 69 years of age, was diagnosed with metastases to meninges and. Depocyt dosage: 50 Mg; 1x; Inth. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ). Patient was hospitalized.

5684204-6 | Apnoeic Attack, Back Pain, Confusional State, Convulsion, Electroencephalogram Abnormal, Headache, Intracranial Pressure Increased, Nausea, Nervous System Disorder
Adverse event was reported on Mar 27, 2008 by a Female patient taking Depocyt (View Usage) (Dosage: 50mg Once It) was diagnosed with metastases to meninges and. Location: UNITED STATES , 43 years of age, weighting 127.9 lb, Patient had the following side effects: apnoeic attack, back pain (What is back pain?), confusional state, convulsion, electroencephalogram abnormal, headache (What is headache?), intracranial pressure increased, nausea (What is nausea?), nervous system disorder. During the same period patient was treated with DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), DILANTIN (View Dilantin Review and Dilantin Label ), PREVACID (View Prevacid Review and Prevacid Label ), DECADRON (View Decadron Review and Decadron Label ), B6 (View B6 Review and B6 Label ), M.V.I. (View M.v.i. Review and M.v.i. Label ). Patient was hospitalized.

5671647-X | Diplopia, Encephalitis
on Feb 28, 2008 Female patient from UNITED KINGDOM , 17 years of age, was diagnosed with prophylaxis and was treated with Depocyt (View Usage). After Depocyt was administered, patient had the following side effects: diplopia, encephalitis (What is encephalitis?). Depocyt dosage: 50 Mg; Qom;. During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5671581-5 | Cauda Equina Syndrome, Disease Progression, Faecal Incontinence, Inflammation, Mobility Decreased, Neurotoxicity, Procedural Complication, Urinary Incontinence
on Feb 28, 2008 Female patient from FRANCE , 64 years of age, was diagnosed with central nervous system lymphoma and was treated with Depocyt (View Usage). Patient experienced the following unwanted or unexpected effects: cauda equina syndrome, disease progression, faecal incontinence, inflammation, mobility decreased, neurotoxicity, procedural complication, urinary incontinence (What is urinary incontinence?). Depocyt dosage: 50 Mg;x4;. During the same period patient was treated with MABTHERA (View Mabthera Review and Mabthera Label ), CHLORAMINOPHEN RITUXIMAB (View Chloraminophen-rituximab Review and Chloraminophen-rituximab Label ), CORTANCYL (View Cortancyl Review and Cortancyl Label ), TAHOR (View Tahor Review and Tahor Label ), AMILORIDE HYDROCHLORIDE (View Amiloride Hydrochloride Review and Amiloride Hydrochloride Label ), ALPRESS (View Alpress Review and Alpress Label ), MODOPAR (View Modopar Review and Modopar Label ). Patient was hospitalized.

5650248-3 | Cauda Equina Syndrome, Concomitant Disease Progression
Patient was taking Depocyt (View Usage). Patient had the following side effects: cauda equina syndrome, concomitant disease progression on Feb 18, 2008 from FRANCE Additional patient health information: Female patient , 65 years of age, was diagnosed with central nervous system lymphoma and. Depocyt dosage: 50 Mg, X4;. During the same period patient was treated with MABTHERA (View Mabthera Review and Mabthera Label ), CHLORAMINOPHEN RITUXIMAB (View Chloraminophen-rituximab Review and Chloraminophen-rituximab Label ), CORTICOSTEROID (View Corticosteroid Review and Corticosteroid Label ), TAHOR (View Tahor Review and Tahor Label ), AMILORIDE HYDROCHLORIDE (View Amiloride Hydrochloride Review and Amiloride Hydrochloride Label ), ALPRESS (View Alpress Review and Alpress Label ), MODOPAR (View Modopar Review and Modopar Label ). Patient was hospitalized.

5650246-X | Cauda Equina Syndrome, Hypoproteinaemia, Meningeal Disorder
Adverse event was reported on Feb 20, 2008 by a Female patient taking Depocyt (View Usage) (Dosage: 50 Mg;x6;inth) was diagnosed with lymphoma (What is lymphoma?) and. Location: FRANCE , 50 years of age, After Depocyt was administered, patient had the following side effects: cauda equina syndrome, hypoproteinaemia, meningeal disorder. During the same period patient was treated with DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

5635689-2 | Conus Medullaris Syndrome, Neurotoxicity
on Feb 06, 2008 Female patient from AUSTRIA , 75 years of age, weighting 150.6 lb, was diagnosed with leukaemic infiltration brain and was treated with Depocyt (View Usage). Patient experienced the following unwanted or unexpected effects: conus medullaris syndrome, neurotoxicity. Depocyt dosage: 50 Mg;qom;inth. Patient was hospitalized and became disabled.

5613946-3 | Fall, Gait Disturbance, Leukoencephalopathy, Neurotoxicity
on Jan 21, 2008 Male patient from GERMANY , 61 years of age, weighting 191.8 lb, was diagnosed with metastases to meninges and was treated with Depocyt (View Usage). Patient had the following side effects: fall (What is fall?), gait disturbance, leukoencephalopathy, neurotoxicity. Depocyt dosage: 50 Mg; Qd; Inth.

5608251-5 | Cauda Equina Syndrome, Febrile Bone Marrow Aplasia
Patient was taking Depocyt (View Usage). After Depocyt was administered, patient had the following side effects: cauda equina syndrome, febrile bone marrow aplasia on Jan 10, 2008 from FRANCE Additional patient health information: Female patient , 73 years of age, was diagnosed with acute myeloid leukaemia, central nervous system leukaemia and. Depocyt dosage: 50 Mg; Qow; Inth. During the same period patient was treated with METHOTREXATE (CON.) (View Methotrexate (con.) Review and Methotrexate (con.) Label ), CYTARABINE (CON.) (View Cytarabine (con.) Review and Cytarabine (con.) Label ), CORTICOSTEROIDS (CON.) (View Corticosteroids (con.) Review and Corticosteroids (con.) Label ), AZACITIDINE (CON.) (View Azacitidine (con.) Review and Azacitidine (con.) Label ). Patient was hospitalized.

5582801-X | Circulatory Collapse, Hypotonia, Neurotoxicity, Paresis, Quadriplegia, Spinal Shock
Adverse event was reported on Dec 17, 2007 by a Male patient taking Depocyt (View Usage) (Dosage: 50 Mg;qd;inth) was diagnosed with lymphoma (What is lymphoma?) and. Location: POLAND , weighting 154.3 lb, Patient experienced the following unwanted or unexpected effects: circulatory collapse, hypotonia, neurotoxicity, paresis, quadriplegia, spinal shock. During the same period patient was treated with DAUNORUBICIN HCL (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), ONCASPAR (View Oncaspar Review and Oncaspar Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYTOSINE ARABINOSIDE (View Cytosine Arabinoside Review and Cytosine Arabinoside Label ). Patient was hospitalized and became disabled.

5567369-6 | Muscle Injury, Myositis, Polyneuropathy
on Nov 29, 2007 Male patient from GERMANY , 68 years of age, was diagnosed with central nervous system leukaemia and was treated with Depocyt (View Usage). Patient had the following side effects: muscle injury, myositis (What is myositis?), polyneuropathy. Depocyt dosage: 50 Mg; Inth. During the same period patient was treated with DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

5538459-9 | Cauda Equina Syndrome, Neurotoxicity
on Nov 20, 2007 Female patient from FRANCE , 65 years of age, was diagnosed with central nervous system lymphoma and was treated with Depocyt (View Usage). After Depocyt was administered, patient had the following side effects: cauda equina syndrome, neurotoxicity. Depocyt dosage: 50 Mg;x4. Patient was hospitalized.

5538458-7 | Cauda Equina Syndrome, Meningeal Disorder
Patient was taking Depocyt (View Usage). Patient experienced the following unwanted or unexpected effects: cauda equina syndrome, meningeal disorder on Nov 20, 2007 from FRANCE Additional patient health information: Female patient , 45 years of age, was diagnosed with lymphoma (What is lymphoma?) and. Depocyt dosage: 50 Mg;x6;inth. During the same period patient was treated with DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ). Patient was hospitalized.

5536064-1 | Bedridden, Cerebral Haemorrhage, Cns Ventriculitis, Csf Lymphocyte Count Increased, Csf White Blood Cell Count Positive, Depressed Level Of Consciousness, Disease Progression, Ependymitis
Adverse event was reported on Nov 21, 2007 by a Male patient taking Depocyt (View Usage) (Dosage: 50 Mg; Xl; Inth) was diagnosed with metastases to meninges and. Location: UNITED STATES , 47 years of age, Patient had the following side effects: bedridden, cerebral haemorrhage, cns ventriculitis, csf lymphocyte count increased, csf white blood cell count positive, depressed level of consciousness, disease progression, ependymitis. During the same period patient was treated with DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), RITUXAN (View Rituxan Review and Rituxan Label ).

5519357-3 | Asthenia, Faecal Incontinence, Herpes Virus Infection, Hypoaesthesia, Muscular Weakness, Paresis Anal Sphincter, Urinary Retention
on Aug 06, 2007 Female patient from SWEDEN , 52 years of age, was diagnosed with b-cell lymphoma and was treated with Depocyt (View Usage). After Depocyt was administered, patient had the following side effects: asthenia, faecal incontinence, herpes virus infection, hypoaesthesia, muscular weakness, paresis anal sphincter, urinary retention. Depocyt dosage: 50 Mg;1x;inth. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), ONCOVIN (View Oncovin Review and Oncovin Label ), DELTISON (View Deltison Review and Deltison Label ), MABTHERA (View Mabthera Review and Mabthera Label ), PRIMPERAN INJ (View Primperan Inj Review and Primperan Inj Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ). Patient was hospitalized.

5515911-3 | Myositis, Polyneuropathy
on Oct 29, 2007 Male patient from GERMANY , 68 years of age, was diagnosed with central nervous system leukaemia and was treated with Depocyt (View Usage). Patient experienced the following unwanted or unexpected effects: myositis (What is myositis?), polyneuropathy. Depocyt dosage: 50 Mg; Inth. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ). Patient was hospitalized.

5515376-1 | Bedridden, Cns Ventriculitis, Depressed Level Of Consciousness, Disorientation, Ependymitis, Mental Impairment, Post Procedural Haemorrhage
Patient was taking Depocyt (View Usage). Patient had the following side effects: bedridden, cns ventriculitis, depressed level of consciousness, disorientation, ependymitis, mental impairment, post procedural haemorrhage on Oct 17, 2007 from UNITED STATES Additional patient health information: Male patient , 47 years of age, was diagnosed with metastases to meninges and. Depocyt dosage: 50 Mg; X1; Inth. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), RITUXAN (View Rituxan Review and Rituxan Label ).